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Abstract The majority of knee arthroplasties (KAs) are
performed in patients with osteoarthritis (OA). Although
bone mass may be increased in these patients, subjects with
knee OA may have an increased risk of hip fracture, pos-
sibly due to an increased severity of falls. However, in
patients with KAs, risk of hip fracture has not been studied
extensively. We evaluated the association between KAs
and hip fracture risk in a population-based case–control
study using the Dutch PHARMO Record Linkage System
(1991–2002, n = 33,104). Cases were patients with a ﬁrst
admission for hip fracture; controls were matched by age,
gender, and geographic location. Neither group had a
previous history of fracture. Time since ﬁrst KA was cal-
culated. Analyses were adjusted for disease and drug his-
tory. A 54% increased hip fracture risk was found in
patients who underwent KA (adjusted [adj.] OR = 1.54,
95% CI 1.19–2.00). We found a strong effect modiﬁcation
by age in these patients: the youngest patients (aged
18–70 years) were at more increased risk for hip fracture
(adj. OR = 2.76, 95% CI 1.16–6.59), while we could not
detect a statistical increase in patients aged [80 years.
Furthermore, the association tended to be greater during the
ﬁrst few years after surgery, although it did not reach sta-
tistical signiﬁcance. We found that KAs are associated with
a 54% increased risk of hip fracture, in particular among
adult patients aged\71 years old. Fracture risk assessment
could be considered in patients who are about to undergo a
KA.
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DOI 10.1007/s00223-011-9558-1Knee arthroplasties (KAs) are effective interventions, with
low mortality rates and few severe adverse outcomes [1].
The surgery is primarily performed in patients with pri-
mary osteoarthritis (OA) and rheumatoid arthritis. In Fin-
land, 81% of patients who underwent KA were diagnosed
with OA (48,607 surgeries between 1980 and 2003) [2]. In
Sweden, 87% of the interventions were in patients with OA
and 10% in patients with rheumatoid arthritis [3].
Risk of hip fracture may be either decreased or
increased in patients with KA or OA. In frail elderly
patients, KA may protect against hip fracture by reducing
the occurrence of falls. On the other hand, within the ﬁrst
month after KA, muscle strength is often decreased [4],
which can elevate fracture risk.
There is more evidence about the association of knee
OA and fracture. Observational studies have provided
conﬂicting results regarding the risk of hip fracture in
patients with OA. A decreased risk of fractures compared
to control patients has been reported by several epidemi-
ological studies [5–7]. This may be due to an increased
bone mineral density (BMD), even at sites distant to the
OA site [8]. Review of histomorphometric and densito-
metric studies at OA sites of the hip and knee revealed that
cartilage ﬁbrillation could not be differentiated from bony
changes, even in the earliest stages of OA. Moreover, mi-
crofractures of subchondral trabecular bone were less fre-
quently observed in patients with OA compared to controls
[5]. Epidemiological studies have revealed that in cases of
generalized OA there are qualitative and quantitative dif-
ferences, including hypermineralization and increased
content of growth factors, suggesting a more generalized
bone alteration [5]. In contrast, a UK study showed an
increased risk of fracture in patients with knee OA [9],
which may have been the result of an increased severity of
falls in these patients. The aim of this study was to evaluate
the association between KA and the risk of hip fracture.
Methods
Settings and Study Design
A case–control study was performed using the Dutch
PHARMO Record Linkage System (RLS) database
(www.pharmo.nl)[ 10]. The database contains pharmacy
dispensing data (including dispensed drug, type of pre-
scriber, dispensing date, amount dispensed, and written
dosage instructions) of about 1 million Dutch residents,
linked to a nationwide hospital discharge register. Diag-
noses are coded according to the International Classiﬁca-
tion of Diseases, 9th revision (ICD-9). Patients are included
irrespective of health insurance or socioeconomic status
and represent about 7% of the general population. The
PHARMO RLS database has a high level of completeness,
as shown in several independent validation studies [11].
Cases and Control Subjects
Cases were deﬁned as patients who had sustained their ﬁrst
hip fracture during the 10-year study period (1 January
1991 to 31 December 2002, at least 18 years of age). Up to
four controls were selected for each case, matched by year
of birth, gender, and geographic location. Control patients
were registered in the database and had no record for a hip
fracture hospitalization. Cases were assigned the date of
hip fracture hospitalization as their index date. Controls
were assigned the same index date as their case. In a
sensitivity analysis, we restricted the study population to
subjects who were at least 50 years of age at the index date.
KA Deﬁnition
History of primary KA before index date was determined
using ICD-9 surgicalprocedure code 81.54. Time since onset
(‘‘recency’’)oftheKAwasdeterminedbycalculatingthetime
between theindexdateandthe earliesthospitaladmissionfor
the KA. We created a proxy for unilateral/bilateral KA by
stratifyingKA patientsinto(1)subjectswithone primaryKA
record before the index date and (2) those with multiple pri-
mary KA records before the index date.
In a sensitivity analysis, we stratiﬁed patients who had
undergone a KA to the region of the body in which OA was
recorded. We used ICD-9 codes 715.6 (OA of lower leg) as
well as 715.0–715.5 and 715.7–715.9 (OA of other or
unspeciﬁed regions) to identify a history of OA. In addi-
tion, time since onset of OA was calculated similarly to
that of time since KA.
Statistical Analysis
Odds ratios (ORs) for fracture risk were estimated using
conditional logistic regression (SAS version 9.1.3, PHREG
procedure; SAS Institute, Cary, NC). The following risk fac-
tors were considered as potential confounders: use of benzo-
diazepines in the 3 months before the index date [10]; use of
bronchodilators, inhaled corticosteroids, oral corticosteroids
[12, 13], statins [14], antipsychotics [15], lithium [16], anti-
depressants [17], beta-blockers [18], opioids (tramadol and
stronger), antiepileptics, thiazide diuretics [19], renin–angio-
tensin–aldosterone system inhibitors, acid suppressants [20],
two or more dispensings of a nonsteroidal anti-inﬂammatory
drug (NSAID), disease-modifying antirheumatic drugs,
organic nitrates [21], antidiabetic drugs, bisphosphonates,
hormone-replacement therapy, calcium/vitamin D supple-
ments, digoxin, and other antiarrhythmics within the
6 months before the index date. In addition, a diagnosis of
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123anemia, mental disorders, impaired renal functioning, skin or
subcutaneous disease, any serious injury within the year
before the index date, or a history of malignant neoplasm,
endocrine disorder, cardiovascular disease, obstructive air-
ways disease, inﬂammatory bowel disease, musculoskeletal
diseases (excluding OA), and connective tissue diseases or
rheumatoidarthritiseverbeforeindexdatewereconsideredas
potential confounders. Parameters were included in the ﬁnal
regression model if they independently changed the beta
coefﬁcientforarthroplastywith[5%inthelogisticregression
model. In a sensitivity analysis, we included use of bisphos-
phonates and hormone-replacement therapy within 6 months
before index date in the ﬁnal regression model, regardless of
thechangeinbetacoefﬁcientforarthroplastycausedbythese
treatments. The longitudinal relationship between the risk of
hip fracture and time since KA was visualized using a
smoothingsplineregressionplot(SASversion 9.1.3,GPLOT
procedure). Spline regression has been advocated as an
alternative to categorical analysis [22].
Results
Table 1 shows baseline characteristics of the fracture cases
and controls. As expected (due to matching), cases and
controls had a similar age and gender distribution. Fracture
cases had recently used more medication that has been
associated with fracture, such as oral glucocorticoids and
strong opioid analgesic. Compared to controls, they had
more often a history of comorbid conditions.
Table 2showstherelationshipbetweentimesinceKAand
the risk of hip fracture. In the adjusted analysis, we found a
54% increased risk of hip fracture among patients with KA
(adjusted [adj.] OR = 1.54, 95% conﬁdence interval [CI]
1.16–1.99).Inthesensitivityanalysis,useofbisphosphonates
and hormone-replacement therapy within 6 months before
index date did not substantially change the increased risk
(adj.OR = 1.54,95%CI1.19–2.00).Similarly,theincreased
riskwasnotchangedwhenlookingatsubjectsagedC50 years
only(93.2%ofthestudypopulation;adj.OR = 1.55,95%CI
1.19–2.01). There was a suggestion that the increased risk of
hipfracturewasgreatestintheﬁrstfewyearsaftertheﬁrstKA
(Fig. 1), although there were no statistically signiﬁcant dif-
ferences with time. No substantial differences were found
with regard to the proxy for unilateral (adj. OR = 1.40, 95%
CI 1.01–1.95) and bilateral (adj. OR = 1.81, 95% CI
1.20–2.74) KA (P = 0.34). Furthermore, timing of increased
hip fracture risk following the most recent KA was compa-
rable between the two groups (data not shown).
Table 3 shows that the increase in risk of hip fracture in
patients with KA was highest in patients aged 18–70 years
(adj. OR = 2.76, 95% CI 1.16–6.59). The increase in hip
fracture risk rapidly decreased toward baseline levels with
increasing age (Fig. 2): patients aged 71–80 years had an
adj. OR of 1.72 (95% CI 1.15–2.57), while the risk was no
longer elevated in patients who were older than 80 years
(adj. OR = 1.16, 95% CI 0.77–1.75). The increase in risk
of hip fracture tended to be higher in females (adj.
OR = 1.62, 95% CI 1.22–2.15) compared to males (adj.
OR = 0.82, 95% CI 0.33–2.03), although this difference
did not reach statistical signiﬁcance.
KA patients who were dispensed pain relievers (opioids
[tramadolorstronger],paracetamol,ormorethanoneNSAID
prescription) 6 months before the index date did not have a
signiﬁcantlyhigherriskofhipfracture(adj.OR = 1.93,95%
CI 1.28–2.91) compared to patients without a history of pain
reliever use (adj. OR = 1.33, 95% CI 0.93–1.89) 6 months
before(P = 0.17)(Table 3).Similarly,patientswhohadused
oral corticosteroids in the 6 months before (adj. OR = 1.41,
95% CI 0.47–4.21) were at the same risk of hip fracture
comparedtopatientswithoutuseoforalcorticosteroidsinthe
same period (adj. OR = 1.56, 95% CI 1.18–2.05).
Table 4 shows that the association between KA and hip
fracture did not substantially change when KAs were
restricted to patients with a history of OA. The proportion
of lower leg OA in patients who had undergone KA was
85%. KA patients with lower leg OA had the same risk of
hip fracture (adj. OR = 1.45, 95% CI 1.08–1.95) compared
Table 1 Characteristics of hip fracture cases and controls
Characteristic Cases (%) Controls (%)
(n = 6,763) (n = 26,341)
Gender
Female 4,929 (72.9) 19,138 (72.7)
Age (years)
18–70 1,641 (24.3) 6,554 (24.9)
71–80 2,144 (31.7) 8,496 (32.3)
[80 2,978 (44.0) 11,291 (42.9)
Use 6 months prior to index date
Oral glucocorticoids 366 (5.4) 918 (3.5)
Paracetamol 882 (13.0) 2,247 (8.5)
[1 NSAID 929 (13.7) 2,584 (9.8)
Opioids 253 (3.7) 455 (1.7)
DMARDs 115 (1.7) 202 (0.8)
Antipsychotics 412 (6.1) 921 (3.5)
Calcium/vitamin D supplements 362 (5.4) 894 (3.4)
Hospitalization ever prior to index date
Osteoarthritis 220 (3.3) 773 (2.9)
Rheumatoid arthritis 245 (3.6) 731 (2.8)
Musculoskeletal/connective tissue
disease (excluding osteoarthritis)
469 (6.9) 1,328 (5.0)
Endocrine disorders 199 (2.9) 381 (1.4)
Obstructive airway disease 266 (3.9) 643 (2.4)
NSAID Nonsteroidal anti-inﬂammatory drug, DMARD disease-
modifying antirheumatic drug
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123to KA patients without correction of lower leg OA (adj.
OR = 1.54, 95% CI 1.19–2.00).
Discussion
This study showed a 1.5-fold increased hip fracture risk in
patients who had undergone a KA. The risk of hip fracture
was greatest in young patients (18–70 years). With
increasing age, we found a rapid decrease in strength of
association, which was no longer elevated in patients aged
81 years and above. The association tended to be greater
during the ﬁrst few years after surgery, but it did not reach
statistical signiﬁcance. Recent use of pain relievers or
glucocorticoids did not alter the overall risk of hip fracture.
This is the second study that has evaluated risk of hip
fractureinpatientswithahistoryofKAandisinlinewiththe
ﬁrst study,whichshoweda 58% increasedriskofhipfracture
in British patients within the ﬁrst year after their KA [23].
Studies that investigated the association between OA (the
main indication for KA) and risk of hip fracture have yielded
conﬂicting ﬁndings. Some authors suggested a decreased
fracture rate among patients with OA [5–7], possibly due to
higher BMD levels [8]. Although data are controversial,
patients with OA may have increased osteoblastic activity at
the OA site, resulting into higher BMD levels and therefore
lower fracture rates [5]. On the other hand, others reported an
increased hip fracture risk, which is in line with our study
results. Bergink et al. [24] found an increased risk of both
vertebral (2.0-fold) and nonvertebral (1.5-fold) fractures in
patients with knee OA. Similarly, Arden et al. [9]d e m o n -
strated that patients with knee pain or a clinician diagnosis of
knee OA have an increased risk of hip and nonvertebral
fractures. This is probably explained by an increased severity
of falls since they could not detect an increased number of
falls.Itshouldbenoted,however,thatdatacollectiononfalls
is often incomplete. This could explain the results of a dif-
ferentstudythatfoundanincreasedoccurrenceoffallsamong
patients with lower limb OA [25]. Furthermore, looking at
differences in fracture types, Arden et al. [9] and Vestergaard
et al. [6] found a substantially higher increase in risk of hip
fracture compared to other fractures (such as distal forearm
fractures).Thismaysuggestanimportantroleforthenatureof
falls in patients with knee OA, as explained by Arden et al.
A US case–control study has shown that hip fractures tend to
result from falling sideways or straight down (low walking
speed),whereasforearmfracturesmaybemorelikelytobethe
result of falling backward [26]. However, Bergink et al. [24]
could not demonstrate a difference between hip and wrist
fractures. Overall, our ﬁndings support the studies that found
Table 2 Risk of hip fracture with knee arthroplasty
Cases (%) Controls (%) Crude OR
(95% CI)
Adj. OR
(95% CI)
a (n = 6,763) (n = 26,341)
Never knee arthroplasty 6,674 (98.7) 26,133 (99.2) 1.00 Referent 1.00 Referent
Ever knee arthroplasty 89 (1.3) 208 (0.8) 1.69 (1.32–2.18)* 1.54 (1.19–2.00)*
\2 years before index 28 (0.4) 69 (0.3) 1.60 (1.03–2.49)* 1.43 (0.89–2.29)
2–5 years before index 40 (0.6) 79 (0.3) 2.01 (1.37–2.96)* 1.96 (1.31–2.92)*
[5 years before index 21 (0.3) 60 (0.2) 1.37 (0.83–2.26) 1.08 (0.63–1.85)
By number of primary KA records before index
One KA record 53 (0.8) 135 (0.5) 1.54 (1.11–2.12) 1.40 (1.01–1.95)
Multiple KA records 36 (0.5) 73 (0.3) 1.98 (1.33–2.96) 1.81 (1.20–2.74)
OR Odds ratio, adj adjusted, CI conﬁdence interval
* Statistically signiﬁcant differences compared to referent
a Adjusted for use of benzodiazepines within 3 months prior, use of bronchodilators, antipsychotics, antidepressants, opioids, antiepileptics,
disease-modifying antirheumatic drugs, calcium/vitamin D supplements, a history of anemia, skin or subcutaneous disease, or serious injuries
1 year prior, malignant neoplasms, endocrine disorders, cardiovascular disease, obstructive airway disease, inﬂammatory bowel disease, mus-
culoskeletal/connective tissue disease (excluding osteoarthritis), or rheumatoid arthritis ever before index date
Fig. 1 Smoothed spline visualization of the relationship between
time since ﬁrst KA and adjusted risk of hip fracture. Dashed lines
represent 95% conﬁdence interval bands. Adjusted for confounders as
shown in Table 2
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123an increased hip fracture risk, indicating that the increased
number and severity of falls may attenuate any potentially
beneﬁcial effects of higher BMD levels on fracture risk in
these patients.
Given this proposed mechanism, we would have expected
hip fracture rates to decrease after the KA procedure as the
surgery relieves pain and partially restores the biomechanical
properties of the knee. However, evidence regarding this
hypothesis is conﬂicting. One study reported fewer falls
within 1 year after the KA [27], while a recent Danish study
couldnotdetectanydecreasesinhipfractureratesduringthat
period [6]. In line with the Danish study and the British study
mentioned earlier [23], we found no obvious decrease in hip
fracture risk shortly after the surgery. A possible explanation
for our ﬁndings is that patients become rapidly more active
after their KA, due to effective knee pain relief [28]. An
overestimation of their physical stability may therefore
increasetheriskoffalls.Thiscouldalsoexplainourobserved
effect modiﬁcation by age: the youngest patients were at
highest hip fracture risk. Compared with elderly patients,
these patients may be more likely to increase their physical
activity quickly after surgery. In addition, residual knee pain
andstiffnessintheﬁrstmonthsaftersurgerymaybepresentin
some KA patients and could further explain our observed
increased hip fracture risk.
Strengths of our study include its population-based set-
ting and that it had a reasonable sample size and longitu-
dinal data collection [10, 12–14]. Linkage with the Dutch
National Hospitalization Registry assured routinely col-
lected KA surgeries and hip fractures. Limitations include
the lack of data on physical activity, which could be an
alternative explanation for our observed association
between KA and hip fracture. Physical activity is signiﬁ-
cantly increased in KA patients within 9 months postop-
eratively [28], while a rapid increase could potentially
initiate falls. In addition, we did not have data on body
mass index (BMI), which could have underestimated our
observed association between KA and hip fracture. An
increased BMI is a well-known risk factor for knee OA
[29], while it is inversely associated with risk of hip frac-
ture [30]. Nevertheless, our ﬁndings are similar to the BMI
Table 3 Risk of hip fracture
with knee arthroplasty stratiﬁed
by gender, age and medication
use
OR Odds ratio, adj adjusted,
CI conﬁdence interval
*Statistically signiﬁcant
differences
a Adjusted confounders as
shown in Table 2 compared to
referent, except for the stratiﬁed
covariate of interest
b Opioids (tramadol or
stronger), paracetamol, or more
than one NSAID prescription
Cases (%) Controls (%) Crude OR
(95% CI)
Adj. OR
(95% CI)
a (n = 6,763) (n = 26,341)
Never knee arthroplasty 6,674 (98.7) 26,133 (99.2) 1.00 Referent 1.00 Referent
Ever knee arthroplasty 89 (1.3) 208 (0.8) 1.69 (1.32–2.18)* 1.54 (1.19–2.00)*
By gender
Males 7 (0.1) 24 (0.1) 1.17 (0.50–2.74) 0.82 (0.33–2.03)
Females 82 (1.2) 184 (0.7) 1.76 (1.35–2.29)* 1.62 (1.22–2.15)*
By age (years)
18–70 13 (0.2) 13 (0.0) 4.18 (1.90–9.19)* 2.76 (1.16–6.59)*
71–80 43 (0.6) 95 (0.4) 1.82 (1.26–2.63)* 1.72 (1.15–2.57)*
[80 33 (0.5) 100 (0.4) 1.27 (0.85–1.89) 1.16 (0.77–1.75)
By use of pain relievers
b 6 months before
Yes 43 (0.6) 75 (0.3) 2.25 (1.55–3.28)* 1.93 (1.28–2.91)*
No 46 (0.7) 133 (0.5) 1.37 (0.97–1.92) 1.33 (0.93–1.89)
By use of oral corticosteroids 6 months before
Yes 6 (0.1) 12 (0.0) 1.94 (0.73–5.18) 1.41 (0.47–4.21)
No 83 (1.2) 196 (0.7) 1.68 (1.29–2.17)* 1.56 (1.18–2.05)*
By use of calcium/vitamin D supplements 6 months before
Yes 7 (0.1) 18 (0.1) 1.77 (0.73–4.30) 1.40 (0.55–3.58)
No 82 (1.2) 190 (0.7) 1.64 (1.25–2.15)* 1.56 (1.18–2.06)*
Fig. 2 Smoothed spline visualization of the association between ﬁrst
KA and adjusted risk of hip fracture, by age at the index date. Dashed
lines represent 95% conﬁdence interval bands. Adjusted for con-
founders as shown in Table 2
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123adjusted results from the General Practice Research Data-
base (GPRD) study [23]. Similar to the British study [23],
we could not differentiate between the sides of KA or the
sides of hip fracture. This information could be helpful in
understanding the mechanism of the observed increased
risk of hip fracture following KA. Local bone loss may be
induced on the side of the replaced knee, possibly resulting
in an increased fracture risk of the hip on the same side
[31]. The only feasible way to investigate this is to link a
dedicated joint registry to a hospital/general practitioner
database, which has been planned for the UK National
Joint Registry and the GPRD. Furthermore, we did not
have data on BMD or falling, which could have been useful
for the assessment of causality and the underlying mech-
anism. In addition, OA could only be identiﬁed in hospi-
talized patients. Frail, unexposed subject bias may have
occurred if KA patients had lower mortality rates compared
to subjects who had not undergone KA (due to clinical
assessment of operative risk) [32]. This was probably not
the case: Within our control subjects (those without a hip
fracture), proportions of cardiovascular hospitalizations
were not lower in KA patients (6.7%) compared to patients
without a history of KA (4.9%). Unfortunately, we did not
have data on other fracture types (such as distal forearm
fractures). As our data source only keeps track of hospi-
talizations, fractures other than those of the hip would
suffer from underrecording. Although OA diagnosis and
KA surgery have not been validated in this data source, we
expect high completeness for KA registration. Our hospi-
talization source was primarily designed to keep track of
economic parameters (e.g., health-care cost). Given the
high cost of KA surgery, we would expect adequate
recording of this procedure.
In conclusion, we showed that KA was associated with a
54% increased risk of hip fracture, which was not inﬂu-
enced by recent use of pain relievers or corticosteroids. The
increase in risk was highest among younger patients
(\71 years), which may reﬂect a rapid increase in physical
activity immediately after surgery. Risk assessment of hip
fracture could therefore be considered in patients who are
about to undergo a KA. It is worthwhile to evaluate its
health economic impact.
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